Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 2 of 33 · 1556 articles
Identifying genes and pathways involved in IBD can point to new biological mechanisms, potential biomarkers, and future targets for research that may eventually inform diagnosis or treatment.
This trial tested a new monoclonal antibody directed at TLR3 in moderate-to-severe ulcerative colitis to see if it is safe and biologically active.
Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...
This study suggests a relationship between higher ustekinumab trough concentrations and clinical remission in adults with Crohn’s disease, which could be relevant to patients and clinicians considering drug-level...
Noninvasive biomarkers that predict response to anti‑TNF drugs could help personalize treatment decisions and identify early who will achieve long‑term endoscopic remission.
Pyroptosis is a key inflammatory pathway that may drive or modulate IBD activity. Understanding and targeting it could lead to new treatments, but past trial setbacks mean patients should know translation is still...
This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis —...
If validated, differences in tissue QDPR could become a marker to help differentiate UC from CD and to indicate mucosal antioxidant/repair status, which may be relevant for disease monitoring and research into new...
Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger...
This trial explores whether delivering sodium propionate directly to the colon can alter the gut microbiome and immune markers in people with Crohn’s disease and whether it offers similar or added benefits compared with...
Dietary patterns, especially ultra-processed food intake, are increasingly linked to Crohn's disease activity. This trial could provide randomized evidence on whether reducing ultra-processed foods prolongs remission in...
The study focuses on children newly diagnosed with Crohn's disease who start anti-TNF treatment and aims to identify biological and clinical markers tied to complete intestinal healing after one year; results could help...
Based on the title and source metadata, this appears to be a clinical study related to Tests and monitoring. The original article is from pubmed.ncbi.nlm.nih.gov.
Biomarkers of gut barrier integrity and oxidative stress could reveal hidden inflammation, help predict disease progression, and indicate likely treatment response—steps toward more personalized IBD care.
The paper points out that reused patient records and preprocessing choices can change how well gene-expression models appear to predict infliximab response. That matters because such biases could mislead researchers and...
Cure8 found this source from wjgnet.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Biomarkers, and Biomarker. Open the original article for the full details.
This preclinical study suggests clarithromycin may reduce colon inflammation in ulcerative colitis models and identifies Kv1.3 and the Th17/Treg balance as possible mechanisms — findings that could guide future...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from Lipids in Health and Disease.
Updated treat-to-target recommendations affect how inflammation and symptoms are monitored and when treatments should be changed. Clear targets and timing help patients and clinicians make consistent, evidence-informed...
Perianal fistulas are a common, challenging Crohn's complication that often need combined medical and surgical care; understanding local practice patterns helps patients and clinicians anticipate typical treatments and...
Patients and clinicians worry isotretinoin might trigger flares in people with existing IBD. This study suggests that among patients with stable, well-controlled Crohn's or UC, isotretinoin did not generally worsen...
Families and clinicians often wonder whether H. pylori infection in childhood affects risks for asthma, IBD, celiac disease, or other immune-mediated disorders.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from Przegla̜d Gastroenterologiczny.
The study offers a validated tool to estimate risk of postoperative recurrence after ileocolonic resection and shows that postoperative biologic prophylaxis markedly lowers early endoscopic recurrence—information that...
Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
A new dual-targeting combination (IL-23 + α4β7) showed higher endoscopic remission rates than either drug alone in a Phase IIa Crohn's study, suggesting a potential new approach for patients who need better mucosal...
Early antibody signatures could allow earlier identification of people at higher risk for Crohn’s disease or ulcerative colitis, which might eventually enable closer monitoring or preventative research.
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
The study links lower vitamin D and higher TNF‑alpha with greater UC severity and with each other, suggesting these measurable biomarkers may reflect inflammation in ulcerative colitis.
This study tested a blood biomarker (zonulin) tied to gut barrier function and found no evidence of increased intestinal permeability in these Behçet syndrome patients, unlike in the Crohn’s disease group.
Patients with upper GI Crohn’s often have a more aggressive course; this registry analysis suggests they usually respond to biologic drugs similarly to other patients but still carry a higher long-term chance of needing...
If validated, antibody-based signals found years before symptoms could allow earlier risk identification and research into why immune responses precede IBD. That may matter for patients and clinicians interested in early...
PRO2 and PRO3 were recorded far more often than CDAI or HBI in routine care and correlated strongly with those clinician-scored indices, so they may be a practical way to monitor Crohn’s activity and support real-world...
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
The study explores whether people with UC in deep histologic remission can reduce or stop maintenance medications without losing remission — a question many patients and clinicians face because of medication costs, side...
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
The report suggests a dual-targeting antibody combination (IL-23 p19 + α4β7) may achieve higher endoscopic remission than either mechanism alone in a treatment-experienced Crohn's population, which could matter for...
This review summarizes how ulcerative colitis trials have been designed recently and flags common weaknesses (small samples, short follow-up, overreliance on Mayo score). Better-designed trials could produce results that...
If validated, antibody signatures could enable earlier identification of people at higher risk of developing IBD and help predict which patients may develop more severe disease, creating opportunities for earlier...
If validated, antibody-based signatures could enable much earlier detection of IBD and help identify people at risk of more severe Crohn’s disease years before symptoms—potentially opening opportunities for research on...
If validated, blood antibody patterns could allow earlier identification of people at risk for Crohn’s disease or ulcerative colitis — potentially before bowel damage occurs — opening opportunities for earlier monitoring...
Blood platelet indices (PLR, MPV) are simple blood-test measures that may help detect IBD activity and show changes with biologic treatment. If validated, they could offer an inexpensive, noninvasive way to supplement...
A simple, low-cost fecal blood assay for mice can speed and lower the cost of preclinical studies of colorectal cancer and GI diseases. For IBD/Crohn’s research, it offers a way to monitor intestinal bleeding and link it...
Nutritional disorders in IBD (underweight/malnutrition, overweight/obesity, and muscle loss/sarcopenia) are common and affect treatment tolerance, recovery, and quality of life. Knowing how frequent these problems are...
The study identifies a specific fibroblast–macrophage interaction driven by collagen IV that may explain how chronic IBD inflammation progresses to fibrosis and cancer, highlighting possible new molecular targets to...
Children with IBD can present differently than adults and may show early signs outside the gut. The special-issue papers highlight improved, less-invasive diagnostic tools and increasing use of targeted biologic...
